Skip to main content

SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson’s disease?

Annals of Nuclear Medicine volume 26, pages 337–344 (2012)Cite this article

Abstract

Objectives

The differential diagnosis between essential tremor (ET) and Parkinson’s disease (PD) may be, in some cases, very difficult on clinical grounds alone. In addition, it is accepted that a small percentage of ET patients presenting symptoms and signs of possible PD may progress finally to a typical pattern of parkinsonism. Ioflupane, N-u-fluoropropyl-2a-carbomethoxy-3a-(4-iodophenyl) nortropane, also called FP-CIT, labelled with 123I (commercially known as DaTSCAN) has been proven to be useful in the differential diagnosis between PD and ET and to confirm dopaminergic degeneration in patients with parkinsonism. The aim of this study is to identify dopaminergic degeneration in patients with PD and distinguish them from others with ET using semi-quantitative SPECT 123I-Ioflupane (DaTSCAN) data in comparison with normal volunteers (NV), in addition with the respective ones of patients referred as suffering from ET, as well as, of patients with a PD diagnosis at an initial stage with a unilateral presentation of motor signs.

Methods

Twenty-eight patients suffering from ET (10 males plus 18 females) and 28 NV (12 males and 16 females) were enroled in this study. In addition, 33 patients (11 males and 22 females) with an established diagnosis of PD with unilateral limb involvement (12 left hemi-body and 21 right hemi-body) were included for comparison with ET. We used DaTSCAN to obtain SPECT images and measure the radiopharmaceutical uptake in the striatum (S), as well as the caudate nucleus (CN) and putamen (P) in all individuals.

Results

Qualitative (Visual) interpretation of the SPECT data did not find any difference in the uptake of the radiopharmaceutical at the level of the S, CN and P between NV and ET patients. Reduced accumulation of the radiopharmaceutical uptake was found in the P of all PD patients. Semiquantitative analysis revealed significant differences between NV and ET patients in the striatum, reduced in the latter. There was also a significant reduction in the tracer accumulation in the left putamen of patients with right hemi-parkinsonism compared to ET and NV. Patients with left hemi-parkinsonism, demonstrated reduced radioligand uptake in the right putamen in comparison with ET and NV. Clinical follow-up of 20 patients with ET at (so many months afterwards) revealed no significant change in clinical presentation, particularly no signs of PD. Follow-up DaTSCAN performed in 10 of them (so many months afterwards) was negative in all but one. This one had an equivocal baseline study which deteriorated 12 months later.

Conclusions

Our results do not support the hypothesis of a link between essential tremor and Parkinson’s disease. However, it appears that ET patients have a small degree of striatal dopaminergic degeneration. If this is due to alterations in the nigrostriatl pathway or of other origin it is not clear. Follow-up studies of essential tremor patients are warranted to assess progression of disease and to understand better the possible cause for striatal dopaminergic degeneration.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Bernheimer H, Birkmayer W, Hornykiewitz O, Jelinger K, Seitleberger F. Brain dopamine damage and the syndromes of Parkinson and Huntington. J Neurol Sci. 1973;20:415–55.

    Article  PubMed  CAS  Google Scholar 

  2. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson’s disease striatum. Synapse. 1991;9:43–9.

    Article  PubMed  CAS  Google Scholar 

  3. Larsen TA, Calne DB. Essential tremor. Clin Neuropharmacol. 1983;6:185–206.

    Article  PubMed  CAS  Google Scholar 

  4. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson’s disease. Age Ageing. 1999;28:99–102.

    Article  PubMed  CAS  Google Scholar 

  5. Jankovic J, Rajput AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson’s disease. Arch Neurol. 2000;57:369–72.

    Article  PubMed  CAS  Google Scholar 

  6. Quinn N. Parkinsonism-recognition and differential diagnosis. BMJ. 1995;310:447–52.

    Article  PubMed  CAS  Google Scholar 

  7. Cleeves L, Findley LJ, Koller W. Lack of association between essential tremor and Parkinson’s disease. Ann Neurol. 1988;24:23–6.

    Article  PubMed  CAS  Google Scholar 

  8. Errea-Abad JM, Ara-Callizo JR. Comparative clinical study of patients with Parkinson’s disease and essential tremor. Rev Neurol. 1998;27:39–43.

    PubMed  CAS  Google Scholar 

  9. Minen MT, Louis ED. Emergence of Parkinson’s disease in essential tremor: a study of the clinical correlates in 53 patients. Mov Disord. 2008;23:1602–5.

    Article  PubMed  Google Scholar 

  10. Tan EK, Lee SS, Fook-Chong S, Lum SY. Evidence of increased odds of essential tremor in Parkinson’s disease. Mov Disord. 2008;23:993–7.

    Article  PubMed  Google Scholar 

  11. Louis ED, Frucht SJ. Prevalence of essential tremor in patients with Parkinson’s disease vs Parkinson-plus syndromes. Mov Disord. 2007;30(22):1402–7.

    Article  Google Scholar 

  12. Chaudhuri KR, Buxton-Thomas M, Dhawan V, Peng R, Meilak C, Brooks DJ. Long duration asymmetrical postural tremor is likely to predict development of Parkinson’s disease and not essential tremor: clinical follow up study of 13 cases. J Neurol Neurosurg Psychiatry. 2005;76:115–7.

    Article  PubMed  Google Scholar 

  13. Shahed J, Jankovic J. Exploring the relationship between essential tremor and Parkinson’s disease. Parkinsonism Relat Disord. 2007;13:67–76.

    Article  PubMed  Google Scholar 

  14. Jankovic J, Beach J, Schwartz K, Contant C. Tremor and longevity in relatives of patients with Parkinson’s disease, essential tremor, and control subjects. Neurology. 1995;45:645–8.

    Article  PubMed  CAS  Google Scholar 

  15. Yahr MD, Orosz D, Purohit DP. Co-occurrence of essential tremor and Parkinson’s disease: clinical study of a large kindred with autopsy findings. Parkinsonism Relat Disord. 2003;9:225–31.

    Article  PubMed  CAS  Google Scholar 

  16. Ondo WG, Lai D. Olfaction testing in patients with tremor-dominant Parkinson’s disease: is this a distinct condition? Mov Disord. 2005;20:471–5.

    Article  PubMed  Google Scholar 

  17. Rocca WA, Bower JH, Ahlskog JE, Elbaz A, Grossardt BR, McDonnell SK, et al. Increased risk of essential tremor in first-degree relatives of patients with Parkinson’s disease. Mov Disord. 2007;22:1607–14.

    Article  PubMed  Google Scholar 

  18. Booij J, Speelman JD, Horstnink MWIM, Wolters EC. The clinical benefit of imaging striatal dopamine transporters with 123I-FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. Eur J Nucl Med. 2001;28:266–72.

    Article  PubMed  CAS  Google Scholar 

  19. Gerasimou G, Tsolaki M, Bonstanjopoulou S, Liaros G, Papanastasiou E, Balaris V, et al. Findings from molecular imaging with SPET camera and 123I-Ioflupane in the differential diagnosis of Parkinsonism and essential tremor. Hell J Nucl Med. 2005;8:81–5.

    PubMed  Google Scholar 

  20. Booij J, Tissingh G, Boer GJ, Speelman JD, Stool JC, Janssen AG, et al. 123I-β-CIT SPECT shows a pronounced decline of striatal dopamine transporter labeling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1997;62:133–40.

    Article  PubMed  CAS  Google Scholar 

  21. Berendse HW, Booij J, Stoffers D, Ponsen MM, Hijman R, Wolters EC. Presymptomatic detection of Parkinson’s disease. Tijdschr Gerontol Geriatr. 2002;33:70–7.

    PubMed  CAS  Google Scholar 

  22. Brücke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wöber C, et al. Measurement of dopamine degeneration in Parkinson’s disease with 123I-b-CIT and SPECT correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm. 1997;S50:9–24.

    Google Scholar 

  23. Catafau A, Tolosa E. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain parkinsonian syndromes. Mov Disord. 2004;19:1175–82.

    Article  PubMed  Google Scholar 

  24. Gerasimou GP, Aggelopoulou TC, Costa DC, Gotzamani-Psarrakou A. Molecular imaging (SPECT and PET) in the evaluation of patients with movement disorders. Nucl Med Rev. 2006;9:147–53.

    Google Scholar 

  25. Deuschi G, Bain P, Brin M, Ad Hoc Scientific Committee. Consensus statement of the Movement Disorder Society on tremor. Mov Disord. 1998;13(Suppl 3):2–23.

    Google Scholar 

  26. Booij J, Hemelaar JTGM, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal pathway in Parkinson’s disease by 123I-FPCIT SPECT. J Nucl Med. 1999;40:753–61.

    PubMed  CAS  Google Scholar 

  27. Elbie RJ. Report from a US conference on essential tremor. Mov Disord. 2006;21:2052–61.

    Article  Google Scholar 

  28. Jenkins IH, Bain PG, Colebatch JG, Thompson PD, Findley LJ, Frackowiak RS, et al. A positron emission tomography study fro overactivity of cerebellar connections. Ann Neurol. 1993;34:82–90.

    Article  PubMed  CAS  Google Scholar 

  29. Deuschi G, Wienzelburger R, Löffler K, Raethjen J, Stolze H. Essential tremor and cerebellar dysfunction. Clinical and kinematic analysis of intention tremor. Brain. 2000;123:1568–80.

    Article  Google Scholar 

  30. Lou RS, Jankovic J. Essential tremor: a heterogenous disorder. Mov Disord. 1991;41:234–8.

    CAS  Google Scholar 

  31. Antonini A, De Notaris R. PET and SPECT functional imaging in Parkinson’s disease. Sleep Med. 2004;5:201–6.

    Article  PubMed  Google Scholar 

  32. Lee MS, Kim YD, Im JH, Kim HJ, Rinne JO, Bhatia KP. 123I-IPT brain SPECT study in essential tremor and Parkinson’s disease. Neurology. 1999;52:1422–6.

    Article  PubMed  CAS  Google Scholar 

  33. Schwarz M, Groshar D, Inzelberg R, Hocheman S. Dopamine-transporter imaging and visuo-motor testing in essential tremor, practical possibilities of detection of early Parkinson’s disease. Parkinsonism Relat Disord. 2004;10:385–9.

    Article  Google Scholar 

  34. Isaias I, Canesi M, Benti R, Gerundini P, Cilia R, Pezzoli G, et al. Striatal dopamine transporter abnormalities in patients with essentail tremor. Nucl Med Commun. 2008;29:349–53.

    Article  PubMed  CAS  Google Scholar 

  35. Louis ED, Honing LS, Vonsattel JP, Maraganore DM, Borden S, Moskowitz CB. Essential tremor associated with focal nonnigral Lewy bodies: a clinicopathological study. Ann Neurol. 2005;62:1004–7.

    Article  Google Scholar 

  36. Djialdetti R, Nageris BI, Lorberboym M, Treves TA, Melamed E, Yaniv E, et al. [123I]-FP-CIT APSECT and olfaction test in patients with combined postural and rest tremor. J Neural Transm. 2008;115:469–72.

    Article  Google Scholar 

  37. Brooks DJ, Playford ET, Ibanez V, Sawle GV, Thompson PD, Findley LJ, et al. Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa study. Neurology. 1992;42:1554–60.

    Article  PubMed  CAS  Google Scholar 

  38. Breit S, Reimold M, Reishl G, Klockgether T, Wüllner U. [11C]d-threo-methyphenidate PET in patients with Parkinson’s disease and essential tremor. J Neural Transm. 2006;113:187–93.

    Article  PubMed  CAS  Google Scholar 

  39. Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brücke T. [123I]β-CIT and SPECT in essential tremor and Parkinson’s disease. J Neural Transm. 1998;105:1213–28.

    Article  PubMed  CAS  Google Scholar 

  40. Isaias IU, Canesi M, Benti R, Canesi M, Marotta G, Gerundini P, et al. [123I]FP-CIT striatal binding in early Parkinson’s disease patients with tremor dominant vs. akinetic-rigid onset. Neuroreport. 2007;18:1499–502.

    Article  PubMed  Google Scholar 

  41. Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhief A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med. 1998;39:1521–30.

    PubMed  CAS  Google Scholar 

  42. Ishibashi K, Ishii K, Oda K, Kawasaki K, Mizusawa H, Ishiwata K. Regional analysis of age-related decline in dopamine transporters and dopamine D2 receptors in human striatum. Synapse. 2009;63:282–90.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. 2nd Laboratory of Nuclear Medicine, AHEPA University Hospital, Thessasloniki, Greece

    G. Gerasimou, E. Papanastasiou, E. Moralidis, T. Aggelopoulou & A. Gotzamani-Psarrakou

  2. HPP Medicina Molecular, Porto, Portugal

    D. C. Costa

  3. 3rd Neurological Clinic, Papanikolaou Hospital, Thessaloniki, Greece

    S. Bostanjiopoulou

  4. 1st Neurological Clinic, AHEPA University Hospital, Thessaloniki, Greece

    M. Arnaoutoglou

Authors
  1. G. Gerasimou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. C. Costa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Papanastasiou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S. Bostanjiopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Arnaoutoglou
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Moralidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. T. Aggelopoulou
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A. Gotzamani-Psarrakou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Gerasimou.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Gerasimou, G., Costa, D.C., Papanastasiou, E. et al. SPECT study with I-123-Ioflupane (DaTSCAN) in patients with essential tremor. Is there any correlation with Parkinson’s disease?. Ann Nucl Med 26, 337–344 (2012). https://doi.org/10.1007/s12149-012-0577-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-012-0577-4

Keywords

  • Essential tremor
  • Parkinson’s disease
  • DaTSCAN